Drugs / PRT3789
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05639751 | May 2023 → Oct 2025 | metastatic neoplasm, non-small cell lung carcinoma | Prelude Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06682806 | Jun 2025 → Jan 2026 | esophageal cancer, metastatic malignant neoplasm, non-small cell lung carcinoma | Prelude Therapeutics | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2024-10-24 | Prelude Therapeutics | Results Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium preludetx.com ↗
Interim data from ongoing trial of PRT3789 showed additional clinical activity at higher doses in patients with non-small cell lung cancer (NSCLC) |
| 2024-09-13 | Prelude Therapeutics | Results Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial preludetx.com ↗
Overall, of the 26 advanced, heavily pre-treated NSCLC or esophageal patients evaluable for efficacy, 7 had tumor shrinkage. |
| 2024-09-09 | Prelude Therapeutics | Results Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024 preludetx.com ↗
Although PRT3789 as a first-in-class molecule targeting a novel mechanism is early in its development, we are highly encouraged by the safety profile, target engagement and clinical activity we have seen to date. |
| 2024-04-09 | Prelude Therapeutics | Results Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting preludetx.com ↗
Next Generation CDK4/6 Inhibitor, PRT3645, is highly effective in combination with other targeted therapies in preclinical models of breast cancer, CRC and NSCLC |
| 2022-11-14 | Prelude Therapeutics | Regulatory Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update preludetx.com ↗
We made meaningful advancements in the third quarter and to date in the fourth quarter, including FDA clearance for two new INDs, one for PRT3645, a next generation, brain penetrant CDK4/6 inhibitor and one for PRT3789, a novel, first-in-class selective SMARCA2 degrader. |
| 2022-10-18 | Prelude Therapeutics | Regulatory Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader preludetx.com ↗
Clearance of the IND for PRT3789 represents a major milestone for Prelude Therapeutics, as we advance our first-in-class SMARCA2 protein degrader from discovery to the clinic. |
| 2022-03-09 | Prelude Therapeutics | Results Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting preludetx.com ↗
The abstract highlights new preclinical data demonstrating synergistic benefit when PRT1419 was combined with the Company’s novel and selective SMARCA2 degrader, PRT3789, in SMARCA4 deleted lung cancer models. |
All press releases naming this drug 8 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRT3789 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05639751 ↗ |
| Modality | Other / unclassified | “PRT 3789, a first-in-class SMARCA2 targeted protein degrader” NCT06682806 ↗ |
| Route | Intravenous | “PRT3789 will be administered by intravenous infusion” NCT05639751 ↗ |
| Target | SMARCA2 | “a SMARCA2 degrader” NCT05639751 ↗ |